ACLARUBICIN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C42H53NO15
Molecular Weight	811.8679
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(CCC(=O)[C@H](C)O1)O[C@H]2[C@@H](O)C[C@]([H])(O[C@@H]3[C@H](C)O[C@]([H])(C[C@@H]3N(C)C)O[C@H]4C[C@](O)(CC)[C@H](C(=O)OC)C5=CC6=C(C(=O)C7=C(O)C=CC=C7C6=O)C(O)=C45)O[C@H]2C

InChI

InChIKey=USZYSDMBJDPRIF-SVEJIMAYSA-N

InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.toku-e.com/product/aclarubicin_hydrochloride/
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23533247	Inhibitor 8228

Conditions

Condition	Modality	Highest Phase	Product
Small-cell lung cancer 41 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1321008	Primary	Phase II 1144	Unknown Approved Use Unknown
Thyroid cancer 16 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3181249	Primary	Phase II 1144	Unknown Approved Use Unknown
Lymphoma 60 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3867405	Primary	Phase II 1144	Unknown Approved Use Unknown
Gastrointestinal adenocarcinoma 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2206579	Primary	Phase I 424	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Enhancement of chemosensitivity toward anticancer drugs by high expression of caspase-1 in NIH 3T3 cells.	1998 Jan	9491796
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.	2005 Dec	16215684
Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours.	2010 Jul 19	20399885
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003
In vitro antifungal activity of DNA topoisomerase inhibitors.	2012 Apr	21939347

Patents

Sample Use Guides

In Vivo Use Guide

25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week

Route of Administration: Intravenous

In Vitro Use Guide

aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.

Name

Type

Language

ACLARUBICIN

Official Name

English

ACLARUBICIN [JAN]

Common Name

English

ACLACINOMYCIN A

Common Name

English

Aclarubicin [WHO-DD]

Common Name

English

ACLACINOMYCIN A [MI]

Common Name

English

ACLARUBICIN [USAN]

Common Name

English

ACLARUBICIN [MART.]

Common Name

English

NSC-208734

Code

English

aclarubicin [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QL01DB04